Author: Ravi Shankar

– Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer –

-MAPKeeper 301 builds on encouraging Phase 2a results presented at ASCO 2026 including median overall survival (OS) of 17.3 months –

– Global, randomized Phase 3 trial ongoing, with overall survival as the primary endpoint –

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial-in-progress poster describing the design and methodology for MAPKeeper 301, its ongoing pivotal Phase 3 clinical trial evaluating atebimetinib in combination with modified gemcitabine and nab-paclitaxel (mGnP) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC), was presented at the European Society for Medical Oncology (ESMO) Congress 2026 held October 23-27, 2026 in Madrid, Spain.

MAPKeeper 301 is a global, randomized, open-label, multicenter Phase 3 trial designed to evaluate whether atebimetinib, an investigational, once-daily oral deep cyclic inhibitor of MEK, in combination with mGnP can improve overall survival compared with standard-of-care gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic PDAC.

The trial builds on encouraging results from Immuneering’s ongoing Phase 2a study of atebimetinib in combination with mGnP, which were reported at ASCO in June and demonstrated median overall survival of 17.3 months, median progression-free survival of 8.3 months, an objective response rate of 36% and a disease control rate of 82% among 55 patients. These results compare favorably with historical outcomes for standard GnP, although the studies were not conducted head-to-head.

“Pancreatic cancer remains one of the most difficult cancers to treat, and patients with metastatic disease in the first-line setting urgently need new therapies capable of delivering meaningful improvements in survival,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. “Our encouraging Phase 2a results reported at ASCO, including median overall survival of 17.3 months in first-line pancreatic cancer patients, provide a strong foundation for MAPKeeper 301. This pivotal Phase 3 trial is designed to determine whether atebimetinib, in combination with modified chemotherapy, can extend survival compared with the current standard of care. We believe atebimetinib’s differentiated Deep Cyclic Inhibition mechanism, designed to shrink tumors durably, preserve body mass, and minimize side effects, has the potential to transform the treatment of metastatic pancreatic cancer.”

ESMO Congress 2026 Poster Presentation Details:

Title: MAPKeeper 301: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus Standard Gemcitabine and nab-Paclitaxel for Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Abstract Number: 3189TiP
Presentation Type: Trial in Progress
Presentation Date: October 25, 2026
The poster will be available on the publications section of Immuneering’s website following presentation at https://immuneering.com/publications

About MAPKeeper 301

MAPKeeper 301 is a global, randomized, open-label, multicenter Phase 3 clinical trial evaluating atebimetinib in combination with modified gemcitabine and nab-paclitaxel compared with standard gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Patients are randomized 1:1 to receive either:

• Experimental arm: Atebimetinib 320 mg orally once daily in combination with modified gemcitabine 1,000 mg/m² and nab-paclitaxel 125 mg/m², administered on days 1 and 15 of each 28-day cycle.
• Control arm: Standard-of-care gemcitabine 1,000 mg/m² and nab-paclitaxel 125 mg/m², administered weekly for three consecutive weeks followed by one week off.

Randomization is stratified by geography, presence of liver metastases, Eastern Cooperative Oncology Group (ECOG) performance status, and whether metastatic disease is newly diagnosed or recurrent.

The primary endpoint is overall survival. Secondary endpoints include progression-free survival, overall response rate, disease control rate, safety, and quality of life.

Eligible patients must have confirmed metastatic pancreatic adenocarcinoma, measurable disease and an ECOG performance status of 0 or 1 and must not have received prior systemic anticancer therapy.

The study began dosing patients in June 2026 and is currently recruiting patients. Additional information is available at www.mapkeeper301.com and ClinicalTrials.gov (NCT07562152).

About Immuneering Corporation

Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.

Forward-Looking Statements

This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer including modified Gemcitabine/nab-paclitaxel (mGnP); the Phase 2a results presented at ASCO providing a strong foundation for the MAPKeeper 301 trial; the unmet need and that patients with metastatic disease urgently need new therapies capable of delivering meaningful improvements in survival; the trial design, enrollment progress, and timing of results from the MAPKeeper 301 trial.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are a late-stage clinical oncology company with a limited operating history and have not completed any registrational clinical trials; we have incurred significant losses, are not currently profitable and may never become profitable; limitations on our cash runway and potential increases in expenditures; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and changing regulatory standards, and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including the uncertainty of whether positive preclinical or early clinical efficacy and safety results are confirmed in later-stage trials, potential delays in activation of trial sites or enrollment of trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Contact:
Laurence Watts
New Street Investor Relations
laurence@newstreetir.com

Media Contact:
David Caouette
dcaouette@immuneering.com

Technical program builds on historical exploration and resource-focused work at the historic Bullseye Zone

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — Maxus Mining Inc. (“Maxus” or the “Company”) (CSE: MAXM | OTCQB: MXMGF | FRA: R7V) is pleased to announce that it has engaged (the “Engagement”) Understood Mineral Resources Ltd. (“UMR”) to complete technical studies supporting future resource delineation drilling at the Company’s Quarry Antimony Project (“Quarry”, the “Project” or the “Property”) in northern British Columbia (please see Figure 1).

UMR is a geological consulting company specializing in resource geology, geological modelling and geo-statistics. The Engagement represents the next step in Maxus’ systematic advancement of the historic Bullseye Zone, with the program designed to establish a technically supported foundation for future resource delineation drilling and identify work required to support the preparation of a potential future NI 43-101-compliant Mineral Resource Estimate (“MRE”).

Quarry Project Highlights

• Historic Bullseye Zone: Historical work reported estimates of 99,781 tonnes grading 1.42% Pb, 2.24% Zn and 36.3 g/t Ag (historically described as “drill-indicated”), as well as 2.72 Mt grading 3.66% Pb + Zn and 36.3 g/t Ag (original category not classified, three zones).¹ These estimates are historical in nature. A Qualified Person has not done sufficient work to classify the historical estimates as current Mineral Resources or Mineral Reserves, and the Company is not treating the historical estimates as current Mineral Resources or Mineral Reserves.
• Strong Historic Drill Results: Historical drilling at the Bullseye Zone included reported averages of 23.6 m of 1.83% Pb, 2.82% Zn and 56.2 g/t Ag in hole 77-11,² 13.0 m of 0.65% Pb, 2.58% Zn and 42.5 g/t Ag in hole 78-25,² and 6.91 m of 2.42% Pb, 2.43% Zn and 87.7 g/t Ag in hole 80-66.³ Reported intervals represent historical drilled lengths; true widths are not known.
• Path Toward NI 43-101-Compliant MRE: UMR’s technical program is designed to establish a framework for future resource delineation drilling and identify key data gaps, supporting the work required to advance the Bullseye Zone toward a potential future NI 43-101-compliant MRE.
• Drill Spacing Assessment: UMR will review drill spacing and resource classification criteria at eight (8) to ten (10) analogous mineral deposits to inform drill spacing recommendations for future resource-focused exploration at the Project.
• Geological Targeting: UMR will review available historical geological and drilling data to develop preliminary interpretations of potential exploration target areas, supporting the planning and prioritization of future drilling at the Project.
• Recent Exploration Supports Polymetallic Potential: Maxus’ 2025 field program confirmed the polymetallic character of the Project, with rock samples returning up to 234 g/t Ag with 4.67% Pb, 121 g/t Ag with 2.35% Pb and 0.74% Zn, and 52.1 g/t Ag with 9.62% Zn and 0.75% Pb.4

The UMR technical program will follow a phased approach focused on evaluating drill spacing requirements and identifying key data gaps and drilling targets to support future resource delineation drilling at the Project.

“This engagement marks another important step in advancing the resource-focused work at Quarry,” said Ranbir Kalan, Director of Maxus Mining. “UMR’s work will help us evaluate appropriate drill spacing, identify key data gaps, and establish a data-informed blueprint for future delineation drilling, supporting our objective of advancing the historic Bullseye Zone toward a potential future Mineral Resource Estimate.”

Figure 1: Quarry Project Map, outlining historic mineral occurrences and the Bullseye Zone location.

Comments on Reliability of Historical Estimate

The historical estimate for the Property is sourced from Property File PF40196, Suzie Mining Explorations Ltd. Newsletter No. 17, prepared by Keith C. Fahrni, P.Eng., and dated July 14, 1978.¹ The historical estimate is considered relevant to the Company’s ongoing exploration of the Bullseye Zone because it provides an indication of the location and distribution of historically reported mineralization and assists in planning further exploration and verification work. However, the historical estimate does not include sufficient documentation of the assumptions, parameters and estimation methods required to assess it under current CIM Definition Standards and, accordingly, its reliability as a current Mineral Resource cannot be established.

The historical estimate uses terminology and classifications that are not directly comparable to current CIM Definition Standards. The 99,781-tonne estimate was historically described as “drill-indicated,” while the original category of the 2.72 Mt estimate was not classified. There are no directly comparable current CIM categories that can be attributed to these historical classifications.

A Qualified Person has not done sufficient work to classify the historical estimate as current Mineral Resources or Mineral Reserves, and the Company is not treating the historical estimate as current Mineral Resources or Mineral Reserves.

Work that may be required to verify the historical estimate and support the preparation of a potential future Mineral Resource Estimate includes a desktop compilation of historical drill data, confirmatory/twin drilling at appropriate spacing, specific-gravity testing by domain, modern analytical QA/QC with check assays, validation of collar locations and downhole surveys, development of a 3D geological/grade model, and QP verification to CIM standards.

About Understood Mineral Resources Ltd.

Understood Mineral Resources Ltd. is a geological consulting company specializing in resource geology, geological modelling, structural geology, and geo-statistics. UMR provides services including geological interpretation and three-dimensional modelling, mineral resource modelling, drill hole spacing studies, infill drill program design and independent technical reviews of mineral resources.

About the Quarry Antimony Project

The 2,632-hectare Quarry Antimony Project is located on the north side of the Osilinka River, between Tenakhi and Wasi creeks, approximately 46 kilometres northwest of Germansen Landing, British Columbia. The historic Quarry showing is exposed in a limestone quarry, where recrystallized and dolomitized limestones of the Neoproterozoic Ingenika Group host mineralized quartz veins. Documented minerals include sphalerite, galena, cerussite, chalcopyrite, boulangerite, malachite, azurite and possibly stibnite (please see Figure 1).⁵

Historical exploration has identified multiple zones of base and precious metal mineralization across the Project. Historical sampling includes a 1991 sample that returned 20% Sb, , 0.34% Zn, 0.89 g/t Au, 3.8% Cu, 42.5% Pb and 0.65 g/t Ag⁶, while earlier grab samples collected in 1954 averaged 83.5% Pb and 1,576 g/t Ag.⁵

Within the Bullseye Zone, historical estimates reported 99,781 tonnes grading 1.42% Pb, 2.24% Zn and 36.3 g/t Ag (historically described as “drill-indicated”), as well as 2.72 Mt grading 3.66% Pb + Zn and 36.3 g/t Ag across three zones.¹ Historical drilling at the Bullseye Zone also returned reported averages including 23.6 m of 1.83% Pb, 2.82% Zn and 56.2 g/t Ag in hole 77-11 and 6.91 m of 2.42% Pb, 2.43% Zn and 87.7 g/t Ag in hole 80-66.^2,3 Reported intervals represent historical drilled lengths; true widths are not known.

Maxus has completed a comprehensive compilation of available historical drill hole data and incorporated the historical drilling into its geological interpretation and modelling workflow. The current UMR program represents the next stage of this work, providing a technical framework to evaluate future drilling requirements and identify data gaps that would need to be addressed in support of a potential future NI 43-101-compliant Mineral Resource Estimate.

The Project offers reliable, year-round access, supporting ongoing exploration initiatives. The region is underlain by the Neoproterozoic Ingenika Group and Paleozoic rocks of the Big Creek, Otter Lakes, Atan, Razorback and Echo Lake groups.⁵

Community Engagement

Maxus recognizes that meaningful engagement with First Nations and local communities is an important component of responsible mineral exploration. The Company remains committed to maintaining transparent communication, minimizing environmental disturbance, and building respectful long-term relationships as exploration activities progress.

Qualified Person Statement

The scientific and technical information contained in this news release has been reviewed and approved by Morgan Verge, P.Geo., VP Exploration of the Company and a “qualified person” as defined in NI 43-101 – Standards of Disclosure for Mineral Projects. Ms. Verge has reviewed available historical exploration records and supporting technical documentation. Historical results reported by previous operators have not been independently verified by the Qualified Person.

Management further cautions that historical results, discoveries and published resource estimates on adjacent or nearby mineral properties, whether in stated current resource estimates or historical resource estimates, are not necessarily indicative of the results that may be achieved on the Project.

About Maxus Mining Inc.

Maxus Mining Inc. (CSE: MAXM | OTCQB: MXMGF | FRA: R7V) is a mineral exploration company focused on locating, acquiring, and, if warranted, advancing economic mineral properties in premier jurisdictions. The Company is actively progressing its diversified portfolio totaling approximately 16,490 hectares of prospective terrain across British Columbia, Canada.

The Portfolio includes 9,492 hectares across three antimony projects, anchored by the Flagship Alturas Antimony Project, where a recent discovery returned high-grade naturally occurring antimony up to 69.98% Sb^¶. The Hurley Antimony Project, located adjacent to Endurance Gold Corp.’s Reliance Gold Project, where 2024 drilling reported 19.2% Sb and 2.16 g/t Au over 0.5 m^‖, and the Quarry Antimony Project, which hosts historical polymetallic samples grading 0.89 g/t Au, 3.8% Cu, 0.34% Zn, 42.5% Pb, 0.65 g/t Ag, and 20% Sb^‡.

Maxus’ portfolio further includes the 3,875-hectare Lotto Tungsten Project, where a selected 1980 grab sample from a scheelite-bearing quartz vein assayed 10.97% WO₃^§, and the 3,123-hectare Penny Copper Project, which has over 100 years of recorded exploration. Recent work programs at Penny included rock sampling and geological mapping^†, with 2017 sampling returning copper values of 1046 ppm Cu (TK17-149c), 1808 ppm Cu (TK17-28), and 2388 ppm Cu (TK17-12)^†. The Project is strategically located near the historic Sullivan Mine at Kimberley, British Columbia, an area that continues to attract significant exploration activity.

Maxus Mining is committed to advancing its British Columbia projects through targeted exploration programs designed to unlock value across multiple critical mineral systems.

References

1 Fahrni, K.C., 1978. Property File PF40196, Suzie Mining Explorations Ltd, Newsletter #17, July 14, 1978

2 Fahrni, K.C., 1978. Suzie Mining Explorations Ltd. Report to Support Assessment Work Recorded on Carol 1, Carol 2, Carie E and Carie W Groups

3 Coveney, C.J., 1981. Gold Leaf Mining Explorations Ltd. Report on the Beveley Property (Wasi Lake Project)

4 Maxus News Release, March 16, 2026 – Maxus Mining Confirms Strong Polymetallic Results at the Quarry Antimony Property in British Columbia, Canada Link

5 Quarry Minfile Link

6 Maxus News Release, January 6, 2026 – Maxus Mining Highlights Historical Polymetallic Results at the Quarry Project in British Columbia, Canada Link

¶ Equinox Resources – November 8, 2024, ‘Ultra High Grade Naturally Occurring Antimony at Alturas Project with Assays up to 69.98% Sb’ – Link

‖ Endurance Summarizes Antimony Results from the Reliance Gold Project, BC – Best Intervals Include 19.2% Antimony And 2.16 ppm Au Over 0.5 m in 2024 Drilling – February 24, 2025 – Link

‡ Open File 1992-11, Map Number 10.

§ MINFILE No: 082FSW228 – Loto 3, 1980 Grab Sample Link

† NI 43-101 – Technical Report on the Penny Property British Columbia, NTS 82G/12 49° 55° North Latitude -115° 90° West Longitude, Derrick Strickland P.Geo., August 14, 2024.

On Behalf of the Board of Directors

Ranbir Kalan
Director
+1 (778) 374-9699
info@maxusmining.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Maxus’, future growth potential for Maxus and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of copper, gold, tungsten, antimony and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Maxus’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company’s objectives, goals, or future plans with respect to the Project; further exploration work on the Project in the future; the expected benefits of the Engagement; completion of the Engagement; the commencement of drilling or exploration programs in the future. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of exploration and drilling results and the geology, continuity and grade of copper, gold, tungsten, antimony and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/54c1baf8-78ad-43aa-9c9b-e5dc6740bd46

Highest sample returned 1.15% TREO with 1,778 ppm neodymium over half a meter

Vancouver, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — The final assay results from Bardy confirm that more work is warranted at the Québec Property. North American Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: KS82.F) (OTCQB: NIOMF) (NIOB or the Company) has now received results for every hole, with every hole returning at least one interval at or above 0.1% total rare earth oxides (TREO) (see Table 1). Hole BBY-2026-006—hosted by a 10-centimetre allanite-rich pegmatite injection within a mafic intrusive (Figure 1)—returned the highest individual sample: 1.15% TREO with 1,778 ppm neodymium (Nd2O3) over 0.50 m.

“This is a unique rare earth-bearing alkaline dyke system in Grenville province that clearly warrants follow-up,” said Murray Nye, Chief Executive Officer. “Our goal at Bardy was to intersect niobium and rare earth bearing systems, and we believe we have done that. The holes were all collared at targets where radon data, high resolution magnetics, and surface mapping all intersect, and we’re pleased that our approach has borne fruit.”

Bardy drilling confirms a rare earth-bearing intrusive system
Bardy forms part of NIOB’s district-scale critical minerals land package in Québec. With its cross-cutting intermediate to felsic dykes, Bardy is interpreted to be part of a broader alkaline system and the diamond drill program, which covered 1,554 meters over eight holes, resulted in three key pieces of information about the system:

• allanite—initially identified in hand samples by a historical government survey—is present in the system; confirming that rare earth elements are also present.

• Bardy hosts a complex swarm of cross-cutting intermediate to felsic dykes, which can indicate a long-lived system that has the potential for hosting an economic system

•  rare earth mineralization mapped at surface continues at depth.

Other highlights include:

• Results from holes BBY-2026-003, -004, -006, -007 and -008 are detailed in this press release and complete the dataset previously reported for BBY-2026-001, -002 and -005 on September 15, 2026

• New composites include

• • 0.28% TREO over 3.50 m (BBY-2026-004, from 215.50 m)
  • 0.43% TREO over 1.95 m (BBY-2026-006, from 71.00 m) and
  • broader low-grade intervals of 0.10% TREO over 16.00 m (BBY-2026-007) and 0.12% TREO over 10.85 m (BBY-2026-008).

• Neodymium is present: Nd₂O₃, the principal magnet rare earth oxide, ranges from 500 to 1,778 ppm in the reported sub-intervals.

Figure 1: BBY-2026-006 from 8.25 to 8.35 m. Syeno-granitic pegmatite injection with approximately 15% coarse allanite, within the 0.50 m sample (7.95 to 8.45 m) that returned 1.15% TREO and 1,778 ppm Nd₂O₃.

Click here to view image

Table 1: Composite intervals (TREO %) for all 2026 Bardy drill holes, including previously published results, with Nd₂O₃ for sub-intervals at or above 500 ppm.

Hole ID	From (m)	To (m)	Length (m)	TREO (%)	Nd2O3 (ppm)	Rock type
BBY-2026-001	133.75	135.80	2.05	0.43		Syeno-granitic pegmatite and surrounding gneiss
incl.	133.75	134.75	1.00		559	As above
incl.	134.75	135.80	1.05		798	As above
BBY-2026-002	132.40	147.00	14.60	0.12		Monzonite/mangerite cut by small syeno-granitic pegmatitic injections
BBY-2026-003	135.00	137.80	2.80	0.14		Pegmatite and adjacent gneiss
BBY-2026-004	215.50	219.00	3.50	0.28		Syenite with local pegmatite intrusion
incl.	215.50	217.00	1.50		516	As above
BBY-2026-004	259.40	265.85	6.45	0.16		Granite and pegmatite
BBY-2026-005	145.50	146.70	1.20	0.10		Pegmatite dyke with 10% magnetite
BBY-2026-006	7.95	8.45	0.50	1.15	1,778	Mafic intrusive with a 10 cm pegmatitic injection carrying 15% coarse allanite
BBY-2026-006	71.00	72.95	1.95	0.43		Magnetic pegmatite
incl.	71.00	71.70	0.70		659	As above
incl.	71.70	72.95	1.25		671	As above
BBY-2026-006	146.10	147.65	1.55	0.24		Magnetic pegmatite
BBY-2026-007	103.30	119.30	16.00	0.10		Mix of pegmatite, intermediate and felsic intrusions with local gneiss
incl.	104.80	105.30	0.50		548	As above
BBY-2026-008	120.05	130.90	10.85	0.12		Intermediate intrusive (syenitic) cutting through gneiss
incl.	122.00	123.00	1.00		514	As above

Note: Composite intervals were calculated at a cut-off grade of 0.1% TREO with a maximum of 2 m of internal dilution. Nd₂O₃ is shown for single-sample intervals and “incl.” sub-intervals returning 500 ppm or more. All intervals are reported as core lengths. True widths have not yet been determined and will be estimated once the 3D geological model of the dyke swarm is completed. TREO (total rare earth oxides) is the sum of lanthanum oxide (La2O3), cerium oxide (Ce2O3), praseodymium oxide (Pr6O11), neodymium oxide (Nd2O3), samarium oxide (Sm2O3), europium oxide (Eu2O3), gadolinium oxide (Gd2O3), terbium oxide (Tb4O7), dysprosium oxide (Dy2O3), holmium oxide (Ho2O3), erbium oxide (Er2O3), thulium oxide (Tm2O3), ytterbium oxide (Yb2O3), lutetium oxide (Lu2O3) and yttrium oxide (Y2O3).

Drill sections and best individual results

Figure 2: Map of the Bardy sector showing drill-hole traces, interpreted radon anomaly trends and the projected extension of the main dyke.

Click here to view image

Cross-sections are presented from west to east. The BBY-2026-005 section was published on September 15, 2026.

BBY-2026-006: Best result of program from top of the hole
BBY-2026-006 was designed to intersect the Bardy main dyke directly beneath its outcrop, with the hole positioned on the dip and trend of the dyke measured at surface. Small pegmatite injections were intersected above and below the projected position of the dyke, together with a zone of mixed syenite and pegmatite near the bottom of the hole.

The 8.0 m syenitic pegmatite interval (139.70 to 147.70 m) reported on August 4, 2026, returned its best assays at its base, with 0.25% TREO over 0.50 m and 0.24% TREO over 1.05 m (146.10 to 147.65 m).

The best result of the program came near the top of the hole, where a 10 cm allanite-rich pegmatite injection within a mafic intrusive returned 1.15% TREO and 1,778 ppm Nd₂O₃ over the 0.50 m sample (7.95 to 8.45 m).

Table 2: Best individual assay results for BBY-2026-006, TREO (%), and Nd₂O₃ (ppm).

Hole ID	From (m)	To (m)	Length (m)	TREO (%)	Nd2O3 (ppm)	Rock type
BBY-2026-006	7.95	8.45	0.50	1.15	1,778	Mafic intrusive with a 10 cm pegmatitic injection carrying 15% coarse allanite
BBY-2026-006	71.00	71.70	0.70	0.42	659	Magnetic pegmatite
BBY-2026-006	71.70	72.95	1.25	0.43	671	Magnetic pegmatite
BBY-2026-006	146.10	146.60	0.50	0.25		Magnetic pegmatite
BBY-2026-006	146.60	147.65	1.05	0.24		Magnetic pegmatite

Figure 3: Cross-section through BBY-2026-006 with TREO assay results.

Click here to view image

BBY-2026-001, -002, and -004:
BBY-2026-001 and -002 were collared approximately 150 m northeast of BBY-2026-006.

BBY-2026-001 tested the northeast extension of the Bardy main dyke, which BBY-2026-004 may also have tested at depth; BBY-2026-002 tested radon anomaly trends.

BBY-2026-004 returned 0.28% TREO over 3.50 m from 215.50 m in syenite with local pegmatite, and 0.16% TREO over 6.45 m from 259.40 m in granite and pegmatite.

Table 3: Best individual assay results for BBY-2026-001 and -004, TREO (%) and Nd₂O₃ (ppm).

Hole ID	From (m)	To (m)	Length (m)	TREO (%)	Nd2O3 (ppm)	Rock type
BBY-2026-001	104.20	104.95	0.75	0.29		Pegmatite with biotite-magnetite clusters and local radioactivity halo, trace allanite locally
BBY-2026-001	104.95	105.70	0.75	0.31	500	Pegmatite with biotite-magnetite clusters and local radioactivity halo, trace allanite locally
BBY-2026-004	35.40	36.30	0.90	0.24		Pegmatite

Figure 4: Cross-section through BBY-2026-004, -001 and -002 with TREO assay results and composites.

Click here to view image

BBY-2026-003
BBY-2026-003 tested two radon anomaly trends and a possible extension of the Bardy main dyke at depth. It returned 0.14% TREO over 2.80 m from 135.00 m in pegmatite and adjacent gneiss.

Figure 5: Cross-section through BBY-2026-003 with TREO assay results and composite.

Click here to view image

BBY-2026-007 and -008
The easternmost section tested the expected eastern extension of the Bardy main dyke (BBY-2026-007) and three radon anomaly trends (BBY-2026-008).

Both holes returned broad, low-grade intervals: 0.10% TREO over 16.00 m from 103.30 m in BBY-2026-007, in a mix of pegmatite, intermediate and felsic intrusions, and 0.12% TREO over 10.85 m from 120.05 m in BBY-2026-008, in a syenitic intrusive cutting gneiss.

Table 4: Best individual assay results for BBY-2026-008, TREO (%) and Nd₂O₃ (ppm).

Hole ID	From (m)	To (m)	Length (m)	TREO (%)	Nd2O3 (ppm)	Rock type
BBY-2026-008	13.25	14.00	0.75	0.44	708	Pegmatite
BBY-2026-008	14.00	14.60	0.60	0.44	730	Pegmatite
BBY-2026-008	154.90	156.00	1.10	0.28		Pegmatite

Note: Tables 2 to 4 list individual samples; Nd₂O₃ is shown where it is 500 ppm or more.

Figure 6: Cross-section through BBY-2026-007 and -008 with TREO assay results and composites.

Click here to view image

Table 5: Collar coordinates for all 2026 Bardy drill holes.

Hole ID	Easting	Northing	Azimuth (°)	Dip (°)	EOH (m)
BBY-2026-001	619303	5271335	10	-50	150
BBY-2026-002	619303	5271335	190	-50	153
BBY-2026-003	619366	5271174	10	-50	216
BBY-2026-004	619243	5271064	10	-50	276
BBY-2026-005	619142	5271187	0	-50	150
BBY-2026-006	619189	5271242	10	-50	156
BBY-2026-007	619615	5271328	10	-50	153
BBY-2026-008	619615	5271328	190	-50	300

Note: Collar coordinates are UTM NAD83 Zone 18N. Total drilled: 1,554 m.

Sampling, analytical method and quality assurance / quality control
Samples were submitted to SGS Canada Inc., which is independent of the Company and operates an ISO/IEC 17025-accredited analytical facility in Val-d’Or, Québec. Rare earth elements were determined by sodium peroxide fusion with an ICP-MS finish (SGS method GE_IMS91A50).

The reported samples are NQ-size half core, split along the core axis and sampled over intervals of approximately 0.5 to 1.0 m, with the remaining half core retained for reference. Quality control included certified reference materials, blanks and field duplicates inserted into the sample stream (approximately 13% of submitted samples). No material QA/QC issues were identified. Core recovery through the mineralized intervals averaged approximately 95 to 97% and is not considered to have materially affected sample representivity.

Qualified Person
The scientific and technical information contained in this news release has been prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”). Clyde McMillan, P.Geo., a consultant to the Company and a Qualified Person as defined under NI 43-101, has reviewed and approved the technical information contained herein. Mr. McMillan has verified the data disclosed in this news release, including the sampling, analytical and test data underlying the information, through review of the drill logs, sample records, SGS assay certificates and QA/QC results. References to allanite and other minerals are based on visual core logging and hand-sample identification and have not yet been confirmed by petrographic or mineralogical analysis.

Corporate Update
The Company also announces that the Hon. Kerry-Lynne D. Findlay has resigned as a director of the Company. NIOB is grateful for Ms. Findlay’s contributions, insight and service during her tenure on the Board, and the Company wishes her every success in her future endeavours.

ABOUT NORTH AMERICAN NIOBIUM AND CRITICAL MINERALS CORP.
North American Niobium and Critical Minerals Corp. is a North American mineral exploration company focused on the acquisition and development of precious, base, and critical mineral assets. Its portfolio includes the Silver Lake property in British Columbia’s Omineca Mining Division and a district-scale land package covering 29,936 hectares in Quebec’s Grenville Province. The Quebec properties host rare earth element, niobium, and nickel-copper occurrences, expanding the Company’s footprint into critical minerals that are strategically important for energy and defense applications.

ON BEHALF OF THE BOARD OF DIRECTORS:
Murray Nye
Chief Executive Officer
info@northamericanniobium.com | +1 (647) 984-4204

Forward-Looking Statements
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, “will”, “plans”, “continues” and similar expressions, or statements that events, conditions or results “will”, “may”, “could” or “should” occur or be achieved. Forward-looking statements in this news release include, but are not limited to, statements regarding: (i) the interpretation of the Bardy assay results and the geological model of the Bardy sector; (ii) the potential of the Bardy intrusive system to host rare earth element mineralization and the relationship between host rock type and grade; (iii) the Company’s plans for follow-up work, including 3D geological modelling and the estimation of true widths; (iv) the integration and interpretation of airborne radiometric and magnetic survey data and the use of radon surveys as a targeting tool; and (v) further drilling programs at Bardy SE and its timing.

Forward-looking statements are based on assumptions management believes to be reasonable and are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially, including, without limitation: risks that further results may not be consistent with those reported; the inherent uncertainty of visual mineral identification; changes in geological interpretation; the absence of demonstrated continuity of mineralization; risks relating to exploration and development; the availability of financing; laboratory and analytical delays; changes in commodity prices; and the other risk factors discussed in the Company’s continuous-disclosure documents filed under its profile on SEDAR+ at www.sedarplus.ca.

The forward-looking statements in this news release are made as of the date hereof. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release.

 

XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors

Anticipate reporting initial Phase 1 data in the fourth quarter of 2027

Plan to present a trial-in-progress poster for XTX501 at the Society for Immunotherapy of Cancer (SITC) 41^st Annual Meeting

WALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that the first patient has been dosed in its Phase 1/2 clinical trial evaluating XTX501, a PD-1/masked IL-2 (alpha-optimized) bispecific antibody fusion protein, in patients with metastatic non-small cell lung cancer (NSCLC) who have previously received anti-PD(L)-1 therapy. Xilio also plans to present a trial-in-progress poster for XTX501 at the upcoming SITC Annual Meeting, highlighting the design of the Phase 1/2 clinical trial.

“By combining tumor-selective activation of high potency, alpha-optimized IL-2 and inhibition of PD-1/PD-L1 into a single molecule, XTX501 has the potential to become a foundational backbone immunotherapy regimen in both monotherapy and combination settings,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “We believe incorporating masking uniquely positions XTX501 to simultaneously leverage these validated mechanisms to enable precise delivery of high potency IL-2 while minimizing the toxicities observed with non-masked IL-2 therapies. Dosing the first patient with XTX501 marks an important milestone for this program, and we anticipate reporting initial Phase 1 data in metastatic NSCLC in the fourth quarter of 2027.”

“PD-1 bispecifics pair a proven checkpoint target with a second, complementary mechanism that can improve depth and duration of anti-tumor immune response, representing one of the most promising new approaches in immuno-oncology,” said Yariv J. Houvras, M.D., Ph.D., chief medical officer. “IL-2 is a powerful driver of T cell expansion, and recent data for treatment with a PD-1/non-masked IL-2 have provided clinical validation of these complementary mechanisms, including in patients whose tumors have stopped responding to first-generation checkpoint inhibitors. By leveraging our clinically-validated masking technology, we believe XTX501 is uniquely positioned to deliver potent, tumor-selective immune activation while overcoming the toxicity and rapid clearance that have limited non-masked IL-2 therapies.”

Poster Presentation at SITC

Xilio plans to present a trial-in-progress poster at the Society for Immunotherapy of Cancer (SITC) 41^st Annual Meeting, taking place from November 4-8, 2026 in Phoenix, Arizona.

Poster presentation details are as follows:

Title: A First-in-Human Phase 1/2 Study of XTX501, a Bispecific PD-1/Masked IL-2, in Metastatic Non-Small Cell Lung Cancer (NSCLC)
Abstract Number: 542
Presentation Date: Saturday, November 7, 2026
Location: Phoenix Convention Center, North Building, Lower Level: Exhibition Halls 4-5-6

About XTX501 and the Phase 1/2 Clinical Trial

XTX501 is a novel, investigational PD-1/masked IL-2 (alpha-optimized) bispecific antibody fusion protein that combines two complementary mechanisms in a single molecule: selective inhibition of the PD-1/PD-L1 pathway and potent IL-2-driven expansion of T cells. The PD-1 binding arm is designed to selectively direct IL-2 activity to PD-1 positive, antigen-experienced T cells and enhance their function. The IL-2 binding arm incorporates a masked, high potency IL-2 variant with an alpha-optimized receptor binding profile. By leveraging Xilio’s proprietary masking technology, XTX501 aims to overcome IL-2 receptor-mediated clearance, peripheral activity and tolerability challenges associated with non-masked IL-2 therapies.

Xilio is initially evaluating the safety and tolerability of XTX501 as a monotherapy in patients with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors who have previously received anti-PD(L)-1 therapy. The first-in-human, multi-center, open-label Phase 1/2 clinical trial is enrolling patients at multiple sites in the United States. For additional details, please refer to www.clinicaltrials.gov (identifier: NCT07688577).

Xilio plans to report initial Phase 1 data in patients with metastatic NSCLC in the fourth quarter of 2027.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws and regulations, including, without limitation, statements regarding the potential of XTX501 to become a foundational backbone immunotherapy regimen for solid tumors in both monotherapy and combination settings; Xilio’s plans to report initial Phase 1 data in metastatic NSCLC in the fourth quarter of 2027; Xilio’s plans to present a trial-in-progress poster for XTX501 at the upcoming SITC Annual Meeting highlighting the design of the Phase 1/2 clinical trial; and Xilio’s strategy, goals, business plans and focus. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks related to general market conditions and geopolitical uncertainties; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio’s current or future product candidates; Xilio’s ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; initial, preliminary, interim or retrospective preclinical or clinical data or results may not be replicated in or predictive of future preclinical or clinical data or results; Xilio’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio’s product candidates may not support further development of such product candidates; actions of regulatory agencies may affect the initiation, timing and progress of current or future clinical trials; Xilio’s ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio’s need to obtain additional cash resources to advance its pipeline of masked I-O molecules; the impact of international trade policies on Xilio’s business, including U.S. and China trade policies; and Xilio’s ability to maintain its collaboration and license agreements with AbbVie and Gilead. These and other risks and uncertainties are described in greater detail in the sections entitled “Risk Factor Summary” and “Risk Factors” in Xilio’s filings with the U.S. Securities and Exchange Commission (SEC), including Xilio’s most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Investor Contact 
Alex Lobo, Precision AQ
alex.lobo@precisionaq.com

Media Contact 
Josie Butler, 1AB
josie@1abmedia.com

President and CEO David Bibby to provide an update on the Company’s latest developments and strategic growth priorities on October 28, 2026, at 1:00 PM ET

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) (the “Company” or “Hypercharge”), a leading EV charging operator, is pleased to announce that David Bibby, President and CEO, will present at Planet MicroCap Toronto 2026 Powered by MicroCapClub on Wednesday, October 28, 2026, at the Arcadian Court & Loft in Toronto, Ontario.

During the presentation, Mr. Bibby will provide an update on Hypercharge’s latest corporate developments, business performance, and strategic growth priorities, including the Company’s continued expansion across North America. The presentation will be followed by a question-and-answer session.

Presentation Details

• Event: Planet MicroCap Toronto 2026 Powered by MicroCapClub
• Date: Wednesday, October 28, 2026
• Time: 1:00 PM ET (10:00 AM PT)
• Location: Arcadian Court & Loft, Toronto, Ontario
• Live Webcast: Watch the Presentation

Ahead of the presentation, investors are encouraged to watch a recent interview with Mr. Bibby for additional insight into the Company and its business.

Investors attending Planet MicroCap Toronto 2026 who are interested in scheduling one-on-one meetings with Hypercharge management can register through the conference website. For more information about Planet MicroCap Toronto 2026, visit planetmicrocap.com.

Marketing Engagement

The Company has also engaged IBN (Investor Brand Network) (“IBN”), a financial media and communications organization, to support its investor awareness strategy, subject to the acceptance of the TSX Venture Exchange (the “TSXV”). IBN will distribute the Company’s news releases and corporate updates to media outlets and social media channels, including IBN’s Dynamic Brand Portfolio of investor-focused brands, and will help strengthen the Company’s market awareness profile. The engagement remains subject to approval of the TSXV. Provision of Services and payment of compensation pursuant to the engagement will only commence after such approval and are anticipated to begin in 2026/2027.

The Company will pay IBN US$29,000 per quarter (US$58,000 in total) for a 6-month initial term, which the parties may extend. Supplementary marketing services, if requested, may incur additional fees. After the initial term, either party may terminate on 30 days’ notice. No securities will be issued as compensation.

IBN is arm’s length to the Company and, to the Company’s knowledge, neither IBN nor its principals hold any direct or indirect interest in the Company’s securities. IBN is located at 1108 Lavaca Street, Suite 110-IBN, Austin, TX 78701, USA, (512) 354-7000, www.IBN.Ai.

About Hypercharge
Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) is a leading provider of smart electric vehicle (EV) charging solutions for residential and commercial buildings, fleet operations, and other rapidly growing sectors. Driven by its mission to accelerate EV adoption and enable the shift towards a carbon neutral economy, Hypercharge is committed to offering seamless, simple solutions, including industry-leading hardware, innovative and integrated software, and comprehensive services, backed by a robust network of public and private charging stations. Learn more: https://hypercharge.com/.

On behalf of the Company,
Hypercharge Networks Corp.
David Bibby, President & CEO

Contact
Media & Investor Relations:
Kyle Kingsnorth, Head of Marketing
kyle.kingsnorth@hypercharge.com | +1 (888) 320-2633

Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. More particularly and without limitation, this news release contains forward-looking statements regarding Hypercharge’s planned participation in Planet MicroCap Toronto 2026, including the timing and content of the presentation, the availability of the live webcast, and the anticipated question-and-answer session; the anticipated acceptance of the Company’s marketing engagement with IBN by the TSX Venture Exchange; the expected timing and commencement of services under the engagement; and the anticipated benefits of the engagement, including increased investor awareness and market visibility. Forward-looking statements are often identified by terms such as “may”, “could”, “should”, “anticipate”, “will”, “estimates”, “believes”, “intends”, “expects” and similar expressions which are intended to identify forward-looking statements. Forward-looking statements are inherently uncertain, and the actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of the Company. Readers are cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are further cautioned not to place undue reliance on any forward-looking statements, as such information, although considered reasonable by management of the Company at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements contained in this news release are made as of the date of this news release, and are expressly qualified by the foregoing cautionary statement. Except as expressly required by applicable securities law, the Company undertakes no obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

LINCOLNSHIRE, Ill., Oct. 26, 2026 (GLOBE NEWSWIRE) — Camping World Holdings, Inc. (NYSE: CWH) (the “Company”) today announced that its financial results for the third quarter 2026 will be released after the market closes on Monday, November 2, 2026. The Company will host a conference call on Tuesday, November 3, 2026 at 7:30 a.m. Central Time to discuss the financial results.

Investors and analysts are invited to listen to the live audio webcast of the call via the Events & Presentations section of the Company’s IR website, http://investor.campingworld.com. The event will be archived and available for replay for up to one year.

For coverage analysts only:
https://register-conf.media-server.com/register/BIcd349a1261ea4571954f0fed6f763e5a
Upon registering you will receive the dial-in info and a unique PIN to join the call.

About Camping World

Camping World Holdings, Inc., headquartered in Lincolnshire, IL, (together with its subsidiaries) is America’s largest retailer of RVs and related products and services. Through Camping World and Good Sam brands, our vision is to build a business that makes RVing and other outdoor adventures fun and easy. We strive to build long-term value for our customers, employees, and stockholders by combining a unique and comprehensive assortment of RV products and services with a national network of RV dealerships, service centers and customer support centers along with the industry’s most extensive online presence and a highly trained and knowledgeable team of associates serving our customers, the RV lifestyle, and the communities in which we operate. We also believe that our Good Sam organization and family of highly specialized services and plans, including roadside assistance, protection plans and insurance, uniquely enable us to connect with our customers as stewards of an outdoor and recreational lifestyle. With RV sales and service locations in 44 states, Camping World has grown to become the prime destination for everything RV. For more information, visit www.CampingWorld.com.

Contacts

Brett Andress, SVP Corporate Development, and Investor Relations
InvestorRelations@campingworld.com
(866) 895-5330

Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it received written notice on October 23, 2026 (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The Compliance Notice follows Nasdaq’s determination that the closing bid price of the Company’s common shares had been at least $1.00 per share for ten consecutive business days, from October 12 through October 23, 2026. Additional details may be found in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission.

The Compliance Notice relates specifically to the minimum bid price requirement. The Company remains subject to Nasdaq’s other continued listing requirements, and there can be no assurance that it will maintain compliance with the minimum bid price requirement or other continued listing requirements in the future.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations 
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.

The Company’s current therapeutic assets are:

CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.

SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.

Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.

Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.

Cautionary Notice on Forward-Looking Statements

[raza- updated below to conform more closely with Medicus standard for news releases]

Certain information in this news release constitutes “forward-looking statements” or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements concerning the continued listing of the Company’s securities on Nasdaq and the Company’s ability to maintain compliance with the minimum bid price requirement and Nasdaq’s other continued listing requirements.

All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. In addition, forward-looking statements are typically identified by words such as “plan,” “believe,” “goal,” “target,” “aim,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, although the absence of these words or expressions does not mean that a statement is not forward-looking.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2025, and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Companies to combine OPT’s PowerBuoy® platforms and patent portfolio with Stratum’s GPU infrastructure to advance edge AI inference powered by wave, wind, and solar energy

MONROE TOWNSHIP, N.J. and CELEBRATION, Fla., Oct. 26, 2026 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT”) and Stratum Holdings Corp. (NASDAQ: SRTM) (“Stratum”) today announced that they have entered into a non-binding letter of intent (the “LOI”) for a proposed strategic collaboration to demonstrate offshore data center assets powered by renewable wave, wind, and solar energy.

The LOI contemplates that OPT and Stratum negotiate definitive agreements pursuant to which OPT would grant Stratum a limited, non-exclusive license to certain of its PowerBuoy® patents for use in the demonstration program and make available certain prototype PowerBuoy® assets currently on hand, and Stratum would make available certain GPU assets, including its latest generation NVIDIA B300 GPUs, and related integration expertise. Stratum would also pay OPT a monthly retainer under the terms of the definitive agreements. The proposed strategic collaboration would focus on integrating OPT’s PowerBuoy® platforms with Stratum’s high-performance compute hardware to validate the technical feasibility of hosting edge AI inference and related workloads on systems powered primarily by onboard renewable generation, without a power umbilical to shore.

OPT holds more than 60 issued patents worldwide relating to its PowerBuoy® technology, including more than 15 in the U.S., covering buoy architecture, energy conversion, power take-off, control systems, mooring and anchoring, autonomous charging interfaces, communications, and related systems. These patents form the foundation of the PowerBuoy® platform, which is designed to deliver persistent, renewable power and real-time communications in remote marine environments.

Cooling accounts for a significant portion of power consumption in conventional data centers. OPT and Stratum believe that positioning PowerBuoy®-based systems in cooler regions of the ocean could reduce this cooling-related power demand, although this has not yet been demonstrated and will be among the matters tested in the proposed demonstration program.

“This proposed strategic collaboration aligns with OPT’s mission to deliver persistent renewable power and technology integration for critical offshore applications,” said Tracy Pagliara, Acting President and Chief Executive Officer of Ocean Power Technologies. “By combining our patented PowerBuoy® technology with Stratum’s GPU assets, we aim to demonstrate a practical path toward self-powered edge AI infrastructure that operates independently of shore-based power.”

“Stratum is focused on expanding high-performance compute capacity in new environments,” said Nicholas H. Adler, Chief Executive Officer of Stratum Holdings. “Partnering with OPT allows us to explore the potential of renewable-powered offshore platforms combined with our GPU assets for edge AI inference, where local processing can reduce bandwidth requirements and leverage the natural cooling advantages of the marine environment.”

The proposed strategic collaboration’s initial efforts are expected to center on system integration, performance validation, and data collection from demonstration deployments. Results from the program, if any, may inform potential future commercial applications in maritime domain awareness, offshore energy monitoring, scientific sensing, and other remote edge-compute use cases.

About Ocean Power Technologies

Ocean Power Technologies, Inc. (NYSE American: OPTT) provides intelligent maritime systems and services for defense and security, offshore energy, science and research, and offshore wind. Its PowerBuoy® platforms deliver clean, renewable power and real-time data communications for remote maritime and subsea applications. The company also offers the WAM-V® autonomous surface vehicle and Merrows™ software for multi-domain awareness. For more information, visit www.oceanpowertechnologies.com.

About Stratum Holdings

Stratum Holdings Corp. (NASDAQ: SRTM) is an AI infrastructure company focused on GPU leasing and high-performance compute capacity. The company is transitioning from legacy real estate operations to provide scalable compute solutions supporting artificial intelligence workloads. For more information, visit www.stratumholdingscorp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risk that the parties do not negotiate or execute definitive agreements on the terms described or at all; the non-binding nature of the LOI and the ability of either party to terminate discussions; the failure to obtain required board, regulatory, or stockholder approvals; the potential dilution to Stratum stockholders from any issuance of shares as payment of the retainer; the value and liquidity of potential Stratum common stock received by OPT, including restrictions on resale pending registration; the parties’ ability to fund and complete the demonstration program on the anticipated timeline or at all; risks related to the successful integration of technologies, technical performance of demonstration systems, regulatory approvals, and market adoption; and other factors described in the companies’ filings with the Securities and Exchange Commission, including their most recent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Neither company undertakes any obligation to update these forward-looking statements, except as required by law.

Media Contacts

Ocean Power Technologies
Investors: 609-730-0400 x401 or InvestorRelations@oceanpowertech.com
Media: 609-730-0400 x402 or MediaRelations@oceanpowertech.com

Stratum Holdings

Crescendo Communications, LLC
srtm@crescendo-ir.com | (212) 671-1020

BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing coverage for the use of BrainsWay Deep TMS™ in the treatment of patients suffering from obsessive compulsive disorder (OCD).

With this latest expansion, more than 118 million Americans are now covered under insurance policies that provide access to BrainsWay Deep TMS for OCD, marking another important milestone in the Company’s ongoing efforts to broaden patient access to innovative, evidence-based mental health treatments.

“As the first company to receive FDA clearance for a non-invasive brain stimulation treatment for OCD, and the only TMS company to have published data from a randomized, placebo-controlled multicenter pivotal study on its device demonstrating efficacy and safety for this indication, we have established a strong foundation of clinical evidence and leadership in this field,” stated Hadar Levy, Chief Executive Officer of BrainsWay. “Reaching more than 118 million covered lives represents meaningful progress in expanding access to Deep TMS for patients living with this challenging condition. We believe our differentiated clinical evidence, supported by growing real-world experience, continues to strengthen the case for broader payer adoption. We remain committed to working with insurers, healthcare providers, and other stakeholders to expand coverage, reduce barriers to treatment, and make this important therapy available to more patients,” concluded Mr. Levy.

The announcement comes within the broader context of continued momentum in BrainsWay’s reimbursement landscape generally, including the Company’s recent announcement regarding the increase in coverage for its accelerated SWIFT™ protocol in the treatment of major depressive disorder (MDD) patients.

BrainsWay Deep TMS is indicated by the FDA as an intended adjunct treatment for adult patients suffering from OCD. BrainsWay remains the only TMS company to have published data from a randomized, placebo-controlled multicenter study conducted on its device demonstrating the efficacy and safety of the treatment for OCD.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks relating to the Company’s ability to consummate, finance and close proposed or potential investments, inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts: 
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com

Company outlined magnetic navigation as an initial commercial development objective and discussed potential quantum communications and energy harvesting applications at Connecticut research and industry event

Norwalk, CT, Oct. 26, 2026 (GLOBE NEWSWIRE) — Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), an autonomous defense technology company developing and integrating next-generation systems, today announced that Nadab Akhtar and William Skidd participated as invited industry presenters discussing the Company’s antenna technology in QuantumCT’s Phase 3 Pilot Collaboration RFP Convening on Quantum Sensing, held on October 16, 2026 in New Haven, Connecticut.

The event marked the official launch of QuantumCT’s Phase 3 request for proposals process. Convened as part of Connecticut’s growing quantum innovation ecosystem, the program brought together academic researchers and industry participants to examine cross-sector opportunities in quantum sensing and introduce a sensing challenge problem designed to encourage collaboration around practical technical applications.

Quantum Cyber’s presentation, delivered by Nadab Akhtar and William Skidd, Chief of Staff at Project LightShift, introduced the Company’s antenna research and its potential relevance to emerging quantum sensing applications. The speakers identified magnetic navigation, or MagNav, as the first development milestone on the Company’s proposed commercial roadmap, particularly in the context of positioning and navigation where conventional satellite-based systems may be unavailable or degraded. They also discussed potential longer-term research applications in quantum communications and energy harvesting. These use cases remain subject to further research, engineering and validation.

The convening included welcome remarks and framing from QuantumCT and Yale leadership, presentations from previously awarded project teams, and short talks by invited academic and industry speakers addressing relevant expertise and potential collaboration opportunities. Participants also discussed the technical considerations behind QuantumCT’s sensing challenge, possible quantum sensing applications across industry sectors, and the Phase 3 proposal framework, including review criteria and timelines. Breakout discussions and a networking reception offered additional opportunities for researchers and industry participants to exchange ideas.

QuantumCT is a public-private partnership involving the University of Connecticut, Yale University and the State of Connecticut that seeks to accelerate quantum technology research, commercialization and adoption. For Quantum Cyber, the event provided an opportunity to introduce its proposed antenna applications to specialists working at the intersection of research, industry and technology development. The Company also has an operating presence in Connecticut, giving it a regional connection to the broader innovation ecosystem.

Quantum Cyber’s participation was a presentation and discussion opportunity. It did not represent a research award, a funded collaboration, a procurement commitment or selection for funding under QuantumCT’s Phase 3 process.

About Quantum Cyber N.V
Quantum Cyber N.V. (Nasdaq: QUCY) is assembling an AI-powered, quantum-accelerated System-of-Systems autonomous defense platform that integrates drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, command-and-control, and quantum antenna applications under a single Nasdaq-listed company. The Company acquires, licenses, and develops autonomous technologies, deploying them as a coordinated, multi-domain portfolio across air, land, and sea. For more information, visit www.quantum-cyber.ai.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements concerning the development, validation, integration and potential commercialization of the Company’s quantum antenna technology, magnetic navigation applications, quantum communications, energy harvesting, research collaborations and future business opportunities. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual outcomes to differ materially, including technical development and testing risks, financing needs, execution challenges, regulatory matters and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
qucy@arxhq.com